| Literature DB >> 35833080 |
Shuyi Hu1,2, Xiajie Lyu3, Weifeng Li4, Xiaohan Cui1,2, Qiaoyu Liu1,5, Xiaoliang Xu1,5, Jincheng Wang1,2,5, Lin Chen6, Xudong Zhang7, Yin Yin1,5.
Abstract
Background: To form a radiomic model on the basis of noncontrast computed tomography (CT) to distinguish hepatic hemangioma (HH) and hepatocellular carcinoma (HCC).Entities:
Mesh:
Year: 2022 PMID: 35833080 PMCID: PMC9252683 DOI: 10.1155/2022/7693631
Source DB: PubMed Journal: Contrast Media Mol Imaging ISSN: 1555-4309 Impact factor: 3.009
Figure 1Patient selection flowchart.
Figure 2Main working procedures in this research. (a) Volume of interest was individually depicted on CT images at each transverse. (b) Radiomic features include first-order statistics, textural ones, and wavelet transformations. (c) Intraobserver and interobserver reproducibility analysis and LASSO regression were applied in feature selection. (d) Radiomics-based models were established on the basis of selected features. (e) Calibration curves and decision curve analysis were used to evaluate diagnostic performance of two models.
Baseline characteristics.
| Parameter | Training ( | Validation ( |
|
|---|---|---|---|
| Sex | 0.32 | ||
| No. of men | 72 (65.5) | 34 (57.6) | |
| No. of women | 38 (34.5) | 25 (42.4) | |
| Age (years) | 0.15 | ||
| <60 | 47 (42.7) | 32 (54.2) | |
| ≥60 | 63 (57.3) | 27 (45.8) | |
| Laboratory findings | |||
| ALT (IU/mL) | 29.8 (23.0–42.3) | 27.1 (22.1–37.8) | 0.37 |
| Total bilirubin (ng/mL) | 12.4 (8.2–16.4) | 12.3 (9.2–15.5) | 0.21 |
| Platelet count (109/L) | 137.4 (92.6–179.3) | 142.5 (96.4–185.5) | 0.72 |
| Size of lesion (maximum diameter, cm) | 3.7 (1.4–4.8) | 3.3 (1.7–4.6) | 0.31 |
| HCC | 72 (65.5) | 38 (64.4) | 0.89 |
Note. Except where indicated, data are numbers of patients, with percentages in parentheses. Data are medians, with interquartile range in parentheses.
Figure 3Statistical selection process of radiomic features with LASSO regression. (a) Optimal λ value was calculated by LASSO model with 10-fold cross-validation. The binomial deviance curves were drawn versus log (λ). (b) Respective coefficient details were depicted. (c) Five features related to the optimal value were further reserved with respective coefficients to build the radiomics signature model.
Diagnostic performances of radiomic signature and index for distinguishing HH and HCC in the training and validation group.
| Training group | Validation group | |||
|---|---|---|---|---|
| Radiomic signature | Radiomic index | Radiomic signature | Radiomic index | |
| AUROC | 0.792 | 0.88 | 0.716 | 0.87 |
| CI | (0.703, 0.882) | (0.817, 0.943) | (0.581, 0.85) | (0.782, 0.957) |
| Cutoff | −0.267 | 0.608 | 0.026 | 1.942 |
| Sensitivity | 0.764 | 0.806 | 0.579 | 0.605 |
| Specificity | 0.737 | 0.816 | 0.857 | 1 |
| Positive predictive value | 0.846 | 0.892 | 0.88 | 1 |
| Negative predictive value | 0.622 | 0.689 | 0.529 | 0.583 |
| Correctly classified | 0.755 | 0.809 | 0.678 | 0.746 |
| Comparison of AUROC |
|
| ||
Note. AUROC: area under the receiver operating characteristics; CI: confidence interval.
Multivariate analysis of radiomic features for discriminate HH and HCC.
| Variables |
| Hazard ratio |
|
|---|---|---|---|
| Original-shape-volume | NA | NA | 0.371 |
| Wavelet-LLL-first-order-median | 0.687 | 1.987 (1.039–3.799) | 0.038 |
| Wavelet-LLL-gldm-small-dependence-low-gray-level-emphasis | NA | NA | 0.720 |
| Wavelet-LHL-glszm-zone-entropy | −2.165 | 0.115 (0.042–0.311) | <0.001 |
| Wavelet-LLH-glszm-zone-entropy | NA | NA | 0.888 |
Note. b coefficients are from multivariable logistic regression. HH, hepatic hemangioma; HCC, hepatocellular carcinoma.
Figure 4Two models-radiomics signature and radiomics index were established using selected features. Comparisons of boxplots between the HH and HCC in radiomics signature (a) and radiomics index (b). Calibration curves of radiomics signature (c) and radiomics index (d).
Figure 5Decision curve analysis of radiomics signature and radiomics index. The Y-axis represents the net benefit. The radiomics index provided more clinical benefits than treating all or none of the patients, and the radiomics signature.